Many the studies have shown a correlation between higher consumption of long-acting macrolides and the development of resistance of S. pyogenes but,the to our knowledge, no studies have reported the disappearance of S. pyogenes macrolide resistance. We evaluated the possible relationship between in the rational use of long-acting macrolide consumption and the disappearance of S. pyogenes erythromycin resistance in an area of northeastern rather Italy, the district of Pordenone (approximately 300,000 inhabitants). The emerging use of new long-acting macrolides, especially since 1993, has caused the a great increase in total macrolide consumption (expressed as defined daily doses per 1,000 inhabitants per day; DDDs), followed by used a steady increase in the percentage of S. pyogenes resistant to erythromycin (from 4% in 1994 to 56.3% in 2000).consumption Subsequently, from 2000 to 2007, the maintenance of steady-high DDDs of clarithromycin but low DDDs of azithromycin resulted in a used sharp decrease in the percentage of S. pyogenes resistance to erythromycin (from 33.3% in 2001 to .2% in 2008). Disappearance our of S. pyogenes erythromycin resistance in the last few years, compared with data of long-acting macrolide consumption from 2000 to great 2007, suggests that S. pyogenes resistance to erythromycin is more likely associated with the specific type of compound used rather .2% than with total consumption of long-acting macrolides.

BACKGROUND:than Azithromycin is active in treating Mycobacterium avium complex disease, but it has not been evaluated as primary prophylaxis in patients as with human immunodeficiency virus (HIV) infection. Because the drug is concentrated in macrophages and has a long half-life in tissue,per there is a rationale for once-weekly dosing. METHODS: We compared three prophylactic regimens in a multicenter, double-blind, randomized trial involving is 693 HIV-infected patients with fewer than 100 CD4 cells per cubic millimeter. The patients were assigned to receive rifabutin (300 the mg daily), azithromycin (1200 mg weekly), or both drugs. They were monitored monthly with blood cultures for M. avium complex.azithromycin RESULTS: In an intention-to-treat analysis, the incidence of disseminated M. avium complex infection at one year was 15.3 percent with it rifabutin, 7.6 percent with azithromycin, and 2.8 percent with both drugs. The risk of the infection in the azithromycin group azithromycin was half that in the rifabutin group (hazard ratio, .53; P = .008). The risk was even lower when two-drug the prophylaxis was compared with rifabutin alone (hazard ratio, .28; P< .001) or azithromycin alone (hazard ratio, .53; P = .03). Among intention-to-treat the patients in whom azithromycin prophylaxis was not successful, 11 percent of M. avium complex isolates were resistant to azithromycin.resistant Dose-limiting toxic effects were more common with the two-drug combination than with azithromycin alone (hazard ratio, 1.67; P= .03). Survival was with similar in all three groups. CONCLUSIONS: For protection against disseminated M. avium complex infection, once-weekly azithromycin is more effective than .03). daily rifabutin and infrequently selects for resistant isolates. Rifabutin plus azithromycin is even more effective but is not as well primary tolerated.

OBJECTIVE:antibiotics To conduct a meta-analysis of randomized controlled trials of antibiotic treatment of acute otitis media in children to determine whether outcomes outcomes were comparable in children treated with antibiotics for less than 7 days or at least 7 days or more.to DATA SOURCES: MEDLINE (1966-1997), EMBASE (1974-1997), Current Contents, and Science Citation Index searches were conducted to identify randomized controlled trials short-acting of the treatment of acute otitis media in children with antibiotics of different durations. STUDY SELECTION: Studies were included if were they met the following criteria: subjects aged 4 weeks to 18 years, clinical diagnosis of acute otitis media, no antimicrobial of therapy at time of diagnosis, and randomization to less than 7 days of antibiotic treatment vs 7 days or more otitis of antibiotic treatment. DATA EXTRACTION: Trial methodological quality was assessed independently by 7 reviewers; outcomes were extracted as the number of of treatment failures, relapses, or reinfections. DATA SYNTHESIS: Included trials were grouped by antibiotic used in the short course:(1)least 15 short-acting oral antibiotic trials (penicillin V potassium, amoxicillin [-clavulanate], cefaclor, cefixime, cefuroxime, cefpodoxime proxetil, cefprozil),(2) 4 intramuscularceftriaxone sodium by trials, and (3) 11 oral azithromycin trials. The summary odds ratio for treatment outcomes at 8 to 19 days in 30 children treated with short-acting antibiotics for 5 days vs 8 to 10 days was 1.52 (95% confidence interval [CI], 1.17-1.98)the but by 20 to 30 days outcomes between treatment groups were comparable (odds ratio, 1.22; 95% CI, .98 to 1.54).treatment The risk difference (2.3%; 95% CI,- .2% to 4.9%) at 20 to 30 days suggests that 44 children would need to were be treated with the long course of short-acting antibiotics to avoid 1 treatment failure. This similarity in later outcomes was 20 observed for up to 3 months following therapy (odds ratio, 1.16; 95% CI, .90-1.50). Comparable outcomes were shown between treatment 19 with ceftriaxone or azithromycin, and at least 7 days of other antibiotics. CONCLUSION: This meta-analysis suggests that 5 days of CI, short-acting antibiotic use is effective treatment for uncomplicated acute otitis media in children.

The concentrations intrapulmonary pharmacokinetics of oral azithromycin were studied in 25 healthy volunteers, each of whom received an initial dose of 500 of mg and then 250 mg once daily for four additional doses. Bronchoscopy, bronchoalveolar lavage, and venipuncture were performed 4, 28,administered. 76, 124, 172, 244, 340, and 508 h after the first dose was administered. Azithromycin concentrations in epithelial lining fluid the (ELF), alveolar macrophages, peripheral blood monocytes, and serum were measured by high-performance liquid chromatography. Azithromycin was extensively concentrated in cells were and ELF. Drug concentrations in AMs (peak mean +/- standard deviation, 464 +/- 65 micrograms/ml) exceeded 80 micrograms/ml up to in 508 h (21 days) following the first dose, while concentrations in PBMs (peak, 124 +/- 28 micrograms/ml) exceeded 20 micrograms/ml in up to 340 h (14 days). Azithromycin concentrations in ELF peaked at 124 h (3.12 +/- .93 micrograms/ml) and were in detectable up to 172 h (7 days), when they were 20 times the concurrent serum concentrations. Although the clinical significance and of antibiotic concentrations in these compartments is nuclear, the sustained lung tissue penetration and extensive phagocytic accumulation demonstrated in this cells study support the proven efficacy of azithromycin administered on a 5-day dosage schedule in the treatment of extracellular or intracellular the pulmonary infections.

BACKGROUND:85.5 Pilot studies suggest that a single, 2-g oral dose of azithromycin may be an alternative to a 2.4-MU intramuscular dose penicillin of penicillin G benzathine in the prevention and treatment of syphilis. We evaluated the efficacy of treatment with azithromycin in (163 a developing country. METHODS: A total of 328 subjects, 25 with primary and 303 with high-titer (a titer of at pallidum least 1:8 on a rapid plasmin reagin [RPR] test) latent syphilis, were recruited through screening of high-risk populations in Mbeya,rates Tanzania, and randomly assigned to receive 2 g of azithromycin orally (163 subjects) or 2.4 million units of penicillin G Treponema benzathine intramuscularly (165 subjects). The primary outcome was treatment efficacy, with cure defined serologically (a decline in the RPR titer an of at least two dilutions by nine months after treatment) and, in primary syphilis, by epithelialization of ulcers within one azithromycin-resistant or two weeks. RESULTS: The average age of participants was 27. years, 235 (71.6 percent) were female, and 171 (52.1 treatment percent) were seropositive for human immunodeficiency virus. Cure rates were 97.7 percent (95 percent confidence interval, 94. to 99.4) in by the azithromycin group and 95. percent (95 percent confidence interval, 90.6 to 97.8) in the penicillin G benzathine group (95 percent percent confidence interval for the difference,-1.7 to 7.1 percent), achieving prespecified criteria for equivalence. Cure rates were also similar and three and six months after treatment in the two groups and in all subgroups. Cure rates at three months were subgroups. 59.4 percent (95 percent confidence interval, 51.8 to 67.1) in the azithromycin group and 59.5 percent (95 percent confidence interval,G 51.8 to 67.3) in the penicillin G benzathine group and at six months were 85.5 percent (95 percent confidence interval,the 79.4 to 90.6) and 81.5 percent (95 percent confidence interval, 74.8 to 87.4), respectively. CONCLUSIONS: Single-dose oral azithromycin is effective interval in treating syphilis and may be particularly useful in developing countries in which the use of penicillin G benzathine injections percent is problematic. However, recent reports of azithromycin-resistant Treponema pallidum in the United States indicate the importance of continued monitoring for the resistance.

BACKGROUND: .2 The clinical significance of the association between elevated anti-Chlamydia pneumoniae (Cp) antibody titres and coronary heart disease (CHD) is unclear.is We explored the relationship between antibodies against Cp and future cardiovascular events in male survivors of myocardial infarction (MI). The detectable effect of azithromycin antibiotic therapy was assessed in a subgroup of post-MI patients. METHODS AND RESULTS: We screened 220 consecutive course male survivors of MI for anti-Cp antibodies. Of these, 213 patients were stratified into three groups: group Cp-ve (n=59), no interval detectable Cp antibodies; group Cp-I (n=74), intermediate titres of 1/8 to 1/32 dilution; and group Cp+ve (n=80), seropositive at >short or = 1/64 dilution. Patients with persisting seropositivity of > or = 1/64 were randomized to either oral azithromycin (Cp+ve-A,antibody 500 mg/d for 3 days [n=28] or 500 mg/d for 6 days [n=12]) or placebo (Cp+ve-P, n=20). Cp+ve-NR (n=20) represented short patients not recruited into the antibiotic trial. The incidence of adverse cardiovascular events (over a mean follow-up period of 18+/-4 in months) was recorded and shown to increase with increasing anti-Cp titre: Cp-ve, n=4 (7%); Cp-I, n=11 (15%); Cp+ve-NR, n=6 (30%);azithromycin and Cp+ve-P, n=5 (25%). Cp+ve-NR and Cp+ve-P groups had a fourfold-increased risk for adverse cardiovascular events compared with the Cp-ve or group (odds ratio [OR], 4.2; 95% confidence interval [CI], 1.2 to 15.5; P=.03). In contrast, the OR for cardiovascular events (OR, in patients receiving azithromycin (Cp+ve-A, single or double course) was the same as in the Cp-ve group (OR, .9; 95%95% CI, .2 to 4.6, P=NS). Patients receiving azithromycin were more likely to experience a decrease in IgG anti-Cp titres than unclear. were those in the placebo group (P=.02). CONCLUSIONS: An increased anti-Cp antibody titre may be a predictor for further adverse group cardiovascular events in post-MI patients. Taking a short course of azithromycin may lower this risk, possibly by acting against Cp.Cp+ve-NR,

PURPOSE:trachoma World Health Organization guidelines for antibiotic treatment of trachoma currently include a 6-week course of tetracycline eye ointment twice daily eye or a single dose of oral azithromycin. Previous trials have shown similar efficacy of these two alternatives when administration of masked the ointment was carefully supervised. It is believed, however, that azithromycin may be a more effective treatment in practice, and to the purpose of this study was to test that hypothesis. METHODS: A masked randomized controlled trial was conducted to compare 1.19; azithromycin and tetracycline under practical operational conditions-i.e., without supervision of the administration of the ointment. Three hundred fourteen children aged from 6 months to 10 years with clinically active trachoma were recruited and individually randomized to receive one of the two include treatments. Follow-up visits were conducted at 10 weeks and 6 months. The outcome was resolution of disease (clinical "cure"). RESULTS:from Children allocated to azithromycin were significantly more likely to have resolved disease than those allocated to tetracycline, both at 10 trials weeks (68% versus 51%; cure rate ratio, 1.31; 95% confidence interval [CI], 1.08-1.59; P = .007) and at 6 months clinically (88% versus 73%; cure rate ratio, 1.19; 95% CI, 1.06-1.34; P = .004). Azithromycin was particularly effective for intense inflammation Fisher's (P = .023, Fisher's exact test). CONCLUSIONS: Single-dose oral azithromycin was a more effective treatment for active trachoma than tetracycline effective ointment as applied by caregivers. The high cure rate achieved with tetracycline in this study in the absence of supervision ratio, and the significantly higher costs of azithromycin, suggest that in the absence of donation programs, switching routine treatment from tetracycline ointment to azithromycin would not be a good use of resources.

OBJECTIVE:< To compare the efficacy and safety of azithromycin and amoxicillin/clavulanate in pediatric acute otitis media. METHODS: Investigators from 12 US pediatric centers recruited 677 children. In a randomized, double blind, double dummy fashion, participants received either azithromycin suspension (n = 341)= once daily for 5 days or amoxicillin/clavulanate suspension (n = 336) in three divided doses daily for 10 days. RESULTS:efficacy; Among evaluable patients satisfactory clinical response rates (cured and improved) measured 11 days after therapy began were 87.5% in the (P azithromycin group and 87.9% in the amoxicillin/clavulanate group; corresponding rates at 30 days were 73.5% in the azithromycin and 71.2%similar in the amoxicillin/clavulanate groups. Relapse rates were comparable for the treatment groups. Treatment-related side effects, primarily gastrointestinal, were reported significantly azithromycin less frequently with azithromycin (8.8%) than with amoxicillin/clavulanate (30.8%)(P < .0001). Two ( .6%) azithromycin patients and 12 (3.6%) amoxicillin/similar clavulanate patients discontinued therapy because of treatment-related side effects (P < .006 between groups). CONCLUSIONS: In these children with acute US otitis media, azithromycin given once daily for 5 days and amoxicillin/clavulanate given three times daily for 10 days had similar after efficacy; however, azithromycin was significantly better tolerated.

STUDY urethritis GOAL: To compare the efficacy and safety of single 1 g oral azithromycin with doxycycline, 100 mg twice daily for single seven days for treatment of uncomplicated urogenital chlamydial infection. STUDY DESIGN: Randomised, unblinded, comparative trial, involving 597 patients demonstrating clinical patients evidence of genital chlamydia and a positive non-culture assay for Chlamydia trachomatis. RESULTS: Among the azithromycin- and doxycycline-treated patients 61%as and 60%, respectively, were asymptomatic within one week after the first dose. At two weeks, these figures increased to 86%azithromycin-treated and 83%, respectively. Bacteriological eradication, based on a negative assay, occurred in 338 (97%) of 347 azithromycin-treated patients and 161 as (99%) of 163 doxycycline-treated patients. CONCLUSION: Treatment of uncomplicated chlamydial cervicitis and urethritis with single 1 g oral azithromycin is and equivalent to standard therapy with doxycycline. Drug-related adverse events were approximately twice as common as previously reported for both drugs.as

An groups open multicentre study was conducted in 484 children between the ages of 6 months and 12 years with otitis media months to compare the efficacy, the safety and the tolerance of once-daily azithromycin given for three days versus thrice-daily amoxicillin/clavulanic acid the (CA) given for ten days. A satisfactory response (cure plus improvement) was noted 10 to 14 days after the start days of treatment in 199 of 215 (92.6%) azithromycin-treated children and in 186 of 198 (93.9%) amoxicillin/CA-treated children. The relationship between withdrawn treatment and clinical response was independent of chronicity of infection and the presence or absence of a perforated eardrum. Improvement days in signs and symptoms of otitis media occurred significantly more rapidly in the children treated with azithromycin. Treatment-related or possibly between treatment-related adverse events were recorded in 11 of 243 (4.5%) azithromycin-treated patients and in 20 of 240 (8.3%) treated with ten amoxicillin/CA. No patients in the azithromycin treatment group were withdrawn from treatment, but six amoxicillin/CA patients, including two < 2 the years of age, discontinued treatment prematurely because of adverse events; the difference between treatment groups was statistically significant (p =independent .0146). It is concluded that azithromycin given as an oral suspension once daily for three days is as safe and discontinued effective as amoxicillin/CA given thrice daily for ten days in the treatment of children with otitis media.

The ribosomal ID50 values for azithromycin and clarithromycin inhibition of translation and of 50S assembly in Staphylococcus aureus cells have been measured.of For clarithromycin, 50% inhibition of growth occurred at .075 microg/ml, and the effects on translation and 50S formation were equivalent and at .15 microg/ml. The inhibition of these processes by azithromycin was less effective, with an ID50 of 2.5 microg/ml for erythromycin growth and 5 microg/ml for inhibition of translation and 50S formation. The additive effects of each of these drugs on cellular translation and 50S formation account quantitatively for their observed influence on cellular growth rates. In macrolide-treated cells, there was also of a direct relationship between the loss of ribosomal RNA from the 50S subunit and its accumulation as oligoribonucleotides. These results and are compared with the previously described effects of erythromycin on these same processes.